Drug companies—the leading source of lobbyist money—now have "a seat at the table" at the White House and on Capitol Hill as healthcare legislation works its way through Congress. The pharmaceutical industry's political transformation provides an example of Obama's approach to achieving his healthcare goals, which includes negotiation and compromise, even with those that the administration previously portrayed as a source of the problem.